Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib is a kinase inhibitor, meaning it works by blocking a type of enzyme called a kinase, which helps keep the cancer cells from growing.<\/p>\n
Ripretinib was approved for medical use in the United States in May 2020, and in Australia in July 2020. Ripretinib is the first new drug specifically approved in the United States as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).<\/p>\n
QINLOCK\u00ae (ripretinib) tablets, for oral use Initial U.S. Approval: 2020<\/strong><\/p>\n QINLOCK (ripretinib) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n NEWS \/ UPDATES<\/strong><\/p>\n Note:<\/strong><\/em> QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.<\/p>\nIs QINLOCK (ripretinib) available in India?<\/h4>\n
How to get QINLOCK tablets delivered in India?<\/h4>\n
Who can help source QINLOCK tablets in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"QINLOCK (ripretinib) \u2013 GIST therapy in India<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n QINLOCK<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n ripretinib<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n \u2022 Tablets: 50 mg<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Deciphera Pharmaceuticals, LLC,<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n